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Circulating glucocorticoid levels oscillate with a
robust circadian rhythm, yet the physiological rele-
vance of this rhythmicity remains unclear. Here, we
show that modulation of circadian glucocorticoid
oscillation by enhancing its amplitude leads to anxi-
olytic-like behavior. We observed that mice with
adrenal subcapsular cell hyperplasia (SCH), a com-
mon histological change in the adrenals, are less
anxious than mice without SCH. This behavioral
change was found to be dependent on the higher
amplitude of glucocorticoid oscillation, although
the total glucocorticoid secretion is not increased in
thesemice. Genetic and pharmacologic experiments
demonstrated that intermediate opioid peptides
secreted from SCH activate CXCR7, a b-arrestin-
biased G-protein-coupled receptor (GPCR), to aug-
ment circadian oscillation of glucocorticoid levels
in a paracrine manner. Furthermore, recapitulating
this paracrine axis by subcutaneous administration
of a synthetic CXCR7 ligand is sufficient to induce
anxiolytic-like behavior. Adrenocortical b-arrestin-
biased GPCR signaling is a potential target for
modulating circadian glucocorticoid oscillation and
emotional behavior.INTRODUCTION
Glucocorticoids, vital stress hormones released as the end prod-
ucts of the hypothalamic-pituitary-adrenal (HPA) axis, affect
emotional behavior by directly acting on numerous brain regions
(Holsboer and Ising, 2010; McEwen, 2007). When exposed to
stress, the adrenal glands secrete glucocorticoids through the
activation of the HPA axis. Glucocorticoids subsequently send
feedback to the brain and suppress the stress response. A dys-
regulated HPA axis with aberrant glucocorticoid signaling in the
brain is often observed in patients with stress-related disorders,
including anxiety, depression, and posttraumatic stress disorder(de Kloet et al., 2005). Likewise, functionally relevant polymor-
phisms of the glucocorticoid receptor gene are associated with
susceptibility to major depression (van Rossum et al., 2006).
In the absence of stressors, the HPA axis is regulated by the
master pacemaker located in the suprachiasmatic nucleus
(SCN) (Chung et al., 2011; Dickmeis, 2009). Therefore, circulating
glucocorticoid levels oscillate with a robust circadian rhythm.
The circadian timing system allows organisms to align their inter-
nal behavioral and metabolic processes with the external light-
dark cycle (Bass, 2012; Bass and Takahashi, 2010). Disruption
of this circadian alignment can lead to emotional disorders
(Keers et al., 2012; Mansour et al., 2005; Roybal et al., 2007).
Conversely, improvement of circadian abnormalities is likely to
be beneficial for the control of emotional stability (Boivin, 2000;
Bunney and Bunney, 2000). In order to translate circadian time
information into physiologically relevant signals, the master
pacemaker in the SCN synchronizes both subordinate extra-
SCN oscillators in the brain and subordinate oscillators in periph-
eral systems through hormonal and neuronal pathways (Bass
and Takahashi, 2010). The rhythmic secretion of glucocorticoids
and their ability to reset circadian time in peripheral tissues sug-
gest that glucocorticoid signaling acts as one of the time cues
(zeitgebers) required to entrain subordinate oscillators (Balsalo-
bre et al., 2000; Le Minh et al., 2001; Oishi et al., 2005). Given the
pharmacological effects of glucocorticoids in the brain and their
possible roles as a zeitgeber, it is intriguing to hypothesize that
rhythmic glucocorticoid signaling organizes temporal gene
expression profiles across different brain regions, thereby coor-
dinating higher brain functions. Indeed, circadian expression of
the rate-limiting serotonin-producing enzyme tryptophan hy-
droxylase-2 in the dorsal raphe nucleus is totally dependent on
circadian glucocorticoid oscillation (Malek et al., 2007). Thus,
modulation of circadian glucocorticoid oscillation by changing
its period, phase, or amplitude may affect emotional behavior.
Notably, approximately one-half of patients with depression
have been reported to display disturbed circadian glucocorticoid
oscillation such as dampened circadian amplitude with elevated
nadir (Keller et al., 2006; Yehuda et al., 1996). However, the phys-
iological significance of circadian glucocorticoid oscillation in the
regulation of emotional behavior is not fully understood. Possibly
this is because no pharmacological tool exists to manipulate
circadian glucocorticoid oscillation specifically.Cell 155, 1323–1336, December 5, 2013 ª2013 Elsevier Inc. 1323
Figure 1. Proenkephlain A mRNA Is Ex-
pressed in the Subcapsular Cell Hyperplasia
in the Adrenal Cortex
(A) In situ hybridization with cRNA probes for Penk,
Furin, and Pcsk2. The bracket denotes SCH. 2mo,
2 months old; 4mo, 4 months old; 6mo, 6 months
old. White scale bar, 500 mm; black scale bar,
100 mm. (B) The adrenal cortex zonation and the
direction of blood flow.
(C) The structure of the proenkephalin A pre-
cursor protein. SP, signal peptide; MetEnk, Met-
enkephalin; LeuEnk, Leu-enkephalin.
See also Figure S1.Glucocorticoid secretion and behavior can be modulated by
histological changes in the adrenal glands. This is supported by
the fact that pathological lesions in the adrenal cortex, such as
glucocorticoid-producing tumors and dysplasia, cause adreno-
corticotropic hormone (ACTH)-independent Cushing syndrome.
Patientswith Cushing syndrome exhibit psychiatric disturbances
due to chronic glucocorticoid excess with a suppressed HPA
axis (Wolkowitz et al., 2009). The adrenal gland is a highly plastic
tissue that remodels with age (Bland et al., 2003). Development
of subcapsular cell hyperplasia (SCH), a common histological
change distinct from tumors and dysplasia, is known as one of
the characteristics of adrenal tissue remodeling in rodents and
humans (Aiba and Fujibayashi, 2011; Kim et al., 2005; Kovatch
et al., 1986; Yoshida et al., 1986). In this report, we describe
the unexpected effects of adrenal SCH on circulating glucocorti-
coid levels and anxiety-like behaviors. By identifying biological
functions of SCH and analyzing the underlying mechanisms,
we have been able to demonstrate that circadian oscillation of
glucocorticoid levels is involved in the regulation of emotional
behavior and, furthermore, that circadian glucocorticoid oscilla-
tion can bemodulated via a b-arrestin-biasedG-protein-coupled
receptor (GPCR) in the adrenal glands.1324 Cell 155, 1323–1336, December 5, 2013 ª2013 Elsevier Inc.RESULTS
Subcapsular Cell Hyperplasia in the
Adrenal Cortex Expresses
Proenkephalin A mRNA in Mice
While we were studying the expression
of neuropeptide precursor genes in the
adrenal medulla, a neuropeptide-rich tis-
sue, we unexpectedly found that adrenal
SCH cells express Proenkephalin A
mRNA (Figures 1A and 1B). SCH is a com-
mon physiological change, which starts
to appear around 4 months of age and
develops gradually thereafter (Yoshida
et al., 1986). Consistent with this notion,
Proenkephalin A in SCH appeared after
4 months in male mice, whereas the first
appearance occurred at about 6 months
in females. As previously reported, the
adrenal medulla also expresses Proenke-
phalin AmRNA at 2 months of age in both
sexes (Figure 1A) (Jingami et al., 1984).The peptide precursor proenkephalin A is cleaved by prohor-
mone convertases, such as furin and PCSK2, to produce
various opioid peptides, peptide fragments containing the clas-
sical opioid motif (YGGFM [Met-enkephalin; MetEnk] or YGGFL
[LeuEnk]) at the N terminus (Figure 1C) (Dillen et al., 1993).
Previous studies have demonstrated that furin cleaves proen-
kephalin A partially into intermediate fragments, whereas
PCSK2 processes proenkephalin A fully to produce mature
MetEnk and LeuEnk (Breslin et al., 1993). Brains from PCSK2
knockout mice were markedly depleted of mature enkephalins
(Johanning et al., 1998). To assess whether intermediate pep-
tide fragments are produced in mouse adrenal glands, where
Furin, but not Pcsk2, is expressed (Figure 1A), we analyzed tis-
sue peptide extracts by reverse-phase high-performance liquid
chromatography (HPLC) followed by a LeuEnk ELISA that
cross-reacts with intermediate peptides containing a C-termi-
nal LeuEnk sequence. Indeed, we found that the adrenal gland
produces intermediate proenkephalin A-derived fragments,
such as peptide E and peptide I (Figure 1C and Figure S1 avail-
able online).
The adrenal cortex receives its blood supply from small
arteries that form an arteriolar plexus lying within and
below the capsule. The arteriolar plexus then gives rise
to a dense sinusoidal network that runs through the
cortex to the medulla (Figure 1B). Thus, molecules secreted
from SCH can be conveyed centripetally and act on adre-
nocortical cells. This anatomy of portal circulation and Proenke-
phalin A expression in SCH cells prompted us to test whether
the presence of SCH modulates glucocorticoid secretion
in vivo.
SCH Enhances Circadian Glucocorticoid Oscillation in a
Proenkephalin A-Dependent Manner
Since considerable variations in SCH development are ob-
served among individual mice, SCH was evaluated histo-
logically in all mice at the end of experiments. Mice were then
grouped retrospectively based on the presence and absence
of SCH. First, we studied if SCH affects acute stress-induced
glucocorticoid secretion. Mice were subjected to 30 min of
restraint stress, and plasma corticosterone levels were mea-
sured at different time points. Corticosterone levels increased
significantly after restraint stress and returned toward basal
levels at 120 min both in the presence and absence of SCH
(Figure 2A). Second, we performed a dexamethasone sup-
pression test (DST), a measure of negative-feedback inhibition
of the HPA axis. In response to dexamethasone challenge,
corticosterone release was equally suppressed in both groups
(Figure 2B). These results suggest that mice with SCH
maintain a functional HPA axis. Under basal conditions without
stressors, plasma corticosterone levels oscillate with a robust
circadian rhythm. We confirmed an intact circadian corticoste-
rone rhythm with a similar period and phase both in the pres-
ence and absence of SCH (Figures 2C and 2D). Interestingly,
however, we found that circadian peak levels of corticosterone
measured at ZT12 were higher in female mice with SCH as
compared to individuals without this hyperplasia, whereas there
was no difference at other time points (Figure 2D). Consistent
with this finding, the overall levels of corticosterone were not
altered in female mice with SCH (two-way ANOVA, PSCH >
0.05), but the amplitude of circadian corticosterone oscillation
was significantly higher in the presence of SCH (Figures 2D
and 2E). Notably, no difference was observed in males across
the day (Figure 2C).
Circulating ACTH secreted from the pituitary gland is a
major physiological regulator of glucocorticoid production
in vivo. No difference was noted in plasma ACTH levels in
the presence of SCH in females (Figure 2F), supporting our
hypothesis that molecules secreted from SCH cells modu-
late corticosterone production by acting on adrenocortical
cells in a paracrine manner. Other physiological measures
such as body weight and serum biochemical parameters
were also found to be unaffected in the presence of SCH
(Table S1).
Next, we examined whether this endocrinological effect of
SCH is mediated by Proenkephalin A gene expressed in SCH.
In contrast to wild-type (WT) female mice, the effects of SCH
were not observed in female Proenkephalin A knockout
(Penk/) mice (Figure 2G). These data indicate that SCH
enhances circadian glucocorticoid oscillation in a Proenkephalin
A-dependent manner in females.SCH Induces Anxiolytic-like Behavior by Enhancing
Circadian Glucocorticoid Oscillation
Neural circuits underlying emotional behavior are highly sensitive
to alterations in plasma glucocorticoid levels (de Kloet et al.,
2005). Having observed the enhanced glucocorticoid oscilla-
tion with a normal HPA axis in the presence of SCH, we
studied whether this endocrinological change affects emotional
behavior. All behavioral tests were performed at the beginning
of the activity phase. First, general locomotor activity was
measured in the open field test. There was no difference in the
novel environment-induced locomotion in the presence of SCH
(Figure 3A). Importantly, however, female mice with SCH stayed
longer in the central area than females without SCH during the
initial 4 min of the session (Figure 3B). Anxiolytic-like effects of
SCH were further studied in two additional tests assessing
anxiety-like behavior. In the elevated plus maze test, female
mice with SCH showed a higher percentage of open arm entries
and time than females without this hyperplasia (Figure 3C),
although the absolute number of entries into all arms was not
different between the two groups (Figure S2A). To examine
whether this behavioral change is dependent on the altered
glucocorticoid secretion induced by SCH, mice were treated
with a glucocorticoid receptor antagonist. We chose a dose
that does not activate basal HPA axis activity (Figure S2B). Under
this low-dose antagonist treatment (RU486; 20 mg/kg, injected
intraperitoneally 6 hr before circadian peak of glucocorticoid
secretion for 4 days), the anxiolytic-like effects of SCH were
totally abolished (Figure 3D). Concordant with this result, SCH
did not elicit anxiolytic-like behavior in males, which exhibit no
difference in circadian glucocorticoid oscillation (Figures 2C,
3B, and 3E). These results indicate that SCH induces anxio-
lytic-like behavior by enhancing circadian glucocorticoid oscilla-
tion. Glucocorticoid-dependent anxiolytic-like effects of SCH
were also observed in the light-dark box test (Figures 3F and
S2C). Since the enhanced glucocorticoid oscillation is depen-
dent on Proenkephalin A gene expressed in SCH, we performed
behavioral tests using female Penk/ mice. As expected, anxi-
olytic-like effects of SCH were not observed in female Penk/
mice (Figure S2D). We also studied the effects of SCH on
depression-like behavior in the forced swim test. No difference
was noted in this paradigm (Figure S2E).
Since advancing the phase of the sleep/wake cycle can exert
an antidepressant effect (Bunney and Bunney, 2000), we
assessed the effects of SCH on the sleep/wake rhythms by
recording polysomnography (electroencephalogram [EEG] and
electromyogram [EMG]) in female mice. No overt difference
was observed in the phase or amplitude of sleep/wake rhythms
(Figure S2F). Interestingly, however, total awake time was
shorter in mice with SCH (Table S2).
CXCR7 Is a High-Affinity Receptor for BAM22 and
Related Peptides Derived from Proenkephalin A
Having observed the increased glucocorticoid secretion at
ZT12 in a Proenkephalin A-dependent manner in female mice,
we screened possible peptide fragments produced from the
proenkephalin A precursor, including intermediate opioid pep-
tides, for the promotion of glucocorticoid secretion in the pres-
ence and absence of ACTH using adrenocortical cells (H295RCell 155, 1323–1336, December 5, 2013 ª2013 Elsevier Inc. 1325
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Figure 2. SCH Enhances Circadian Glucocorticoid Oscillation in a Proenkephalin A-Dependent Manner
(A) Acute restraint stress-induced glucocorticoid secretion in the presence and absence of SCH (male: n = 3–5/group; female: n = 5–7/group).
(B) Dexamethasone suppression test (male: n = 4–6/group; female: n = 3–6/group). Dexamethasone was injected intraperitoneally 6 hr before the sample
collection.
(C and D) Rhythmic secretion of corticosterone in mice. Higher plasma corticosterone levels at ZT12 (circadian peak) in 6-month-old female wild-type (WT) mice
with the adrenal SCH present. (n = 8–12/group). The overall levels of corticosterone were not altered in female mice with SCH (two-way ANOVA, PSCH > 0.05). The
graphs are double-plotted.
(E) Higher amplitude of circadian corticosterone oscillation in the presence of SCH (n = 8–12/group).
(F) Plasma concentrations of ACTH in 6-month-old female WT mice (n = 8–12/group).
(legend continued on next page)
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Figure 3. SCH Induces Anxiolytic-like
Behavior by Enhancing Circadian Glucocor-
ticoid Oscillation
(A) Open field test. No difference in locomotor
activity between the two groups (male: n = 9/
group; female: n = 16–19/group).
(B) Open field test. Longer center time in females
with SCH (male: n = 9/group; female: n = 16–19/
group).
(C) Elevated plus maze test. The percentage of
open arm entries and time. Female mice with SCH
were less anxious (n = 16–19/group).
(D) Elevated plus maze test. Effects of a gluco-
corticoid receptor antagonist (RU486; 20 mg/kg
for 4 days) on anxiolytic-like behavior induced by
SCH (n = 12–15/group).
(E) Elevated plus maze test. Anxiolytic-like
behavior was not observed in males (n = 9/group).
(F) Light-dark box test. Glucocorticoid-dependent
anxiolytic-like effects of SCH were observed in
females (n = 11–16/group).
Results are shown asmean ± SEM. *p < 0.05; **p <
0.01. See also Figure S2 and Table S2.cells: ATCC.CRL-2128) as a model system. This led to the dis-
covery that BAM22 augments ACTH-induced glucocorticoid
secretion in a dose-dependent manner (Figure 4A). Peptide E,
another BAM22-related peptide, was also found to have compa-
rable activity (Figure S3A). These results coincide with our
hypothesis that SCH cells produce partially processed opioid
peptides (Figures 1A, 1C, and S1). BAM22 and peptide E contain
the MetEnk sequence at the N terminus (Figure S3B). Thus,
BAM22 is able to activate the canonical G-protein-coupled
opioid receptors (d, k, and m) as efficiently as MetEnk, a mature
form of enkephalins (Figure S3C). Importantly, however, MetEnk
did not promote glucocorticoid secretion (Figure 4A), suggesting
that the effects of BAM22may bemediated by a receptor distinct
from opioid receptors. To further examine this hypothesis,
[Phe1]BAM22, a BAM22 mutant that can not activate opioid re-
ceptors (Figure S3C), was tested. [Phe1]BAM22 and BAM22
equally promoted ACTH-induced glucocorticoid secretion (Fig-(G) Plasma concentrations of corticosterone at ZT0 and ZT12 in 6-month-old Proenkephalin A knocko
n = 7–9/group).
The presence of SCH was evaluated histologically by using adrenal sections. Mice were retrospectively gro
Results are shown as mean ± SEM. *p < 0.05; **p < 0.01. ZT, zeitgeber time. See also Table S1.
Cell 155, 1323–1336, Dure 4B). Well-conserved amino acid
sequences of BAM22 and peptide E
also support the idea that they are not
only intermediate peptides for mature
enkephalins, but they may also have
distinct functions per se (Figure S3B).
To identify a BAM22 receptor promot-
ing glucocorticoid secretion, we listed
and screened all peptidergic GPCRs
and peptidergic-like orphan GPCRs ex-
pressed in adrenocortical cells. We em-
ployed a heterologous b-arrestin-GPCR
recruitment assay established in 293Tcells for this purpose. This led to the identification of CXCR7
as a receptor for BAM22 (Figure 4C). CXCR7 had been identified
as a b-arrestin-biased receptor for the chemokines SDF1 and
I-TAC (Burns et al., 2006). Specificity of the interaction was
demonstrated by testing proenkephalin A-derived peptide
fragments against all known chemokine receptors (Figure 4D).
Intermediate peptides (BAM22, peptide E, and peptide I), but
not mature peptides (MetEnk, LeuEnk, and MetEnkRF), specif-
ically activated CXCR7. Dose-response analyses showed that
BAM22, as well as SDF1 and I-TAC, recruit both b-arrestin-1
and b-arrestin-2 at nanomolar concentrations (Figure 4E). As
predicted from the previous finding that CXCR7 does not acti-
vate heterotrimeric G-proteins in response to SDF1 and I-TAC
(Rajagopal et al., 2010), BAM22 elicited neither a cyclic AMP
(cAMP) nor a calcium response in H295R cells as well as in
293T cells overexpressing CXCR7 (293T-CXCR7) (Figures S3D
and S3E). We then demonstrated direct interaction betweenut (Penk/) mice (male: n = 4–9/group; female:
uped based on the presence or absence of SCH.
ecember 5, 2013 ª2013 Elsevier Inc. 1327
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Figure 4. CXCR7 Is a High-Affinity Receptor for BAM22 and Its Related Peptides
(A) Enhanced ACTH-induced cortisol secretion from H295R cells by BAM22, but not by MetEnk.
(B) Comparable effects of [Phe1]BAM22 and BAM22 on ACTH-induced cortisol secretion.
(C) Specific activation of CXCR7 by BAM22 (1 mM) among the receptors expressed in adrenocortical cells in a b-arrestin-2 recruitment assay.
(D) Receptor-specific activation by proenkephalin A fragments. All known chemokine receptors were screened for activation by proenkephalin A-derived
peptides (1 mM) using a b-arrestin-2 recruitment assay.
(legend continued on next page)
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Table 1. BAM22-Related Peptide Potency as Determined by a b-Arrestin-2 Recruitment Assay
Sequence
EC50 (nM)
CXCR7 DOR MRGPRX1
MetEnk YGGFM inactive 13 ± 4 inactive
BAM12 YGGFMRRVGRPE 175 ± 48 228 ± 99 inactive
BAM14 YGGFMRRVGRPEWW 53 ± 10 59 ± 9 inactive
BAM18 YGGFMRRVGRPEWWMDYQ 42 ± 10 54 ± 9 >300
BAM22 YGGFMRRVGRPEWWMDYQKRYG 39 ± 18 147 ± 30 >300
Peptide E YGGFMRRVGRPEWWMDYQKRYGGFL 150 ± 29 >300 >300
BAM30 ELQKRYGGFMRRVGRPEWWMDYQKRYGGFL >300 >300 >300
Peptide I SPQLEDEAKELQKRYGGFMRRVGRPEWWMDYQKRYGGFL >300 >300 >300
[Phe1]BAM22 FGGFMRRVGRPEWWMDYQKRYG 47 ± 12 inactive >300
BAM(2-22) GGFMRRVGRPEWWMDYQKRYG >300 inactive >300
BAM(6-22) RRVGRPEWWMDYQKRYG inactive inactive >300
BAM(8-22) VGRPEWWMDYQKRYG inactive inactive >300
BAM(8-18) VGRPEWWMDYQ inactive inactive inactive
Data represent the mean values ± SEM in three assays. inactive, no response at 3 mM.BAM22 and CXCR7 using a competitive binding assay. Mem-
branes from 293T-CXCR7 were labeled with 125I-SDF1a and
the radioligand binding was displaced by nanomolar concentra-
tions of unlabeled BAM22 (half maximal inhibitory concentration
[IC50] = 16 nM) as well as SDF1a (IC50 = 5 nM) and I-TAC (IC50 =
33 nM) (Figure 4F). In agreement with our results (Figure 4A),
MetEnk did not inhibit 125I-SDF1a binding to CXCR7 (IC50 >
3 mM) (Figure 4F).
A structure-activity relationship study was then performed
(Table 1). We tested CXCR7, d opioid receptor (DOR), and
MRGPRX1 in parallel, since MRGPRX1 was also reported to
be a receptor for proenkephalin A-derived peptides (Lembo
et al., 2002). Among the tested fragments, BAM22 was the
most potent ligand for CXCR7 and, conversely, of all the recep-
tors, BAM22 activated CXCR7 most efficiently. Consistent
with our data in adrenocortical cells (Figure 4B), [Phe1]BAM22
and BAM22 were equally active at CXCR7 in a heterologous
b-arrestin-GPCR recruitment assay (Table 1; Figure S3F).
Furthermore, the BAM22-CXCR7 interaction was insensitive to
naloxone, a classical opioid receptor antagonist (Figure 4G).
Collectively, these results suggested that CXCR7 and the canon-
ical opioid receptors recognize the structure of BAM22
differently.
CXCR7, the Only Opioid Peptide Receptor Expressed in
the Adrenal Cortex, Mediates the Endocrinological
Effects of SCH In Vivo
To investigate whether CXCR7 is expressed in the adrenal gluco-
corticoid-producing cell layer in vivo, we performed in situ hy-
bridization analyses. The expression of Cxcr7 mRNA, but none
of the canonical opioid receptors (Oprd1, Oprk1, and Oprm1)
or Mrgprx1, was identified in adrenal glands of 6-month-old(E) Comparative dose-response of CXCR7 to BAM22, SDF1a and I-TAC using b
(F) Competition of 125I-SDF1a binding to the membrane fractions of 293T-hCXC
(G) Effects of the opioid antagonist naloxone (1 mM) on the BAM22-CXCR7 inter
Results are shown as mean ± SEM. *p < 0.05; **p < 0.01. See also Figure S3.mice (Figure 5A), which is consistent with the previous report
that the adrenal gland is one of the most abundant sites of
Cxcr7 expression in mice (Regard et al., 2008). In 6-month-old
females, Cxcr7 was strongly expressed in the entire layer of
the zona fasciculata, where glucocorticoids are produced. Inter-
estingly, the expression seemed to increase with age. In
contrast, a weaker Cxcr7 expression was detected at the junc-
tion of the cortex and the medulla in males. These results
suggest that, in the adrenal gland, CXCR7 is the only receptor
activated by intermediate opioid peptides. Importantly, the
sex-dependent adrenocortical expression of Cxcr7 explains
why SCH exerts its effects only in females. To examine whether
CXCR7mediates the endocrinological effects of SCH in vivo, we
treated mice with intraperitoneal injections of either CXCR7-
neutralizing antibody (anti-CXCR7 monoclonal antibody [8F11];
10 mg/kg) or isotype control immunoglobulin G2b. In vitro valida-
tion of this neutralizing antibody was performed before the
experiments (Figures S4A and S4B). Under this treatment, the
effects of SCH on circadian glucocorticoid secretion were
abolished (Figure 5B). Together, these results suggest that the
effects of SCH are mediated by proenkephalin A-derived pep-
tides acting on CXCR7.
CXCR7-b-Arrestin-MAPK Pathway Mediates the Effects
of Intermediate Opioid Peptides in Adrenocortical Cells
Similar to the in vivo histological findings (Figure 5A), quantitative
PCR analysis demonstrated that adrenocortical cells (H295R)
express CXCR7 but none of the canonical opioid receptors or
MRGPRX1 (Figure S4C; Table S3). CXCR7 mRNA was also
detected in Y1 cells, another adrenocortical cell line, but its
expression levels were considerably lower than those in H295R
cells (less than 1%) (data not shown). Knockdown experiments-arrestin-1 and 2 recruitment assays.
R7 cells by BAM22, SDF1a and I-TAC.
action in a b-arrestin-2 recruitment assay. DOR, d opioid receptor.
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confirmed that CXCR7 mediates BAM22 actions in H295R cells
(Figures 5C and S4D; Table S3). We thus investigated the
mechanism by which intermediate opioid peptides promote
glucocorticoid secretion utilizing H295R cells as amodel system.
Through the activation of the melanocortin 2 receptor (MC2R),
ACTH elicits G protein-mediated cAMP signaling as well as
phosphorylation of p44/p42 mitogen-activated protein kinases
(p44/p42 MAPKs, also known as ERK1/2) (Janes et al., 2008).
The latter are known to enhance the steroidogenesis induced
by the ACTH-MC2R-cAMP pathway. In contrast to MC2R,
CXCR7 is a b-arrestin-biased receptor. b-arrestins function as
scaffolds that participate in various signaling pathways,
including those of the MAPKs (DeWire et al., 2007). These
considerations suggested a putativemechanistic model in which
BAM22-CXCR7-b-arrestin signaling promotes cortisol secretion
by enhancing ACTH-induced ERK activation (Figure 6A). When
either b-arrestin-1 or b-arrestin-2 was knocked down, BAM22
effects were abolished (Figures 5D and S4E; Table S3), indi-
cating that both b-arrestin-1 and b-arrestin-2 are required. This
type of codependent regulation has been reported in other
receptors as well (DeWire et al., 2007). The ACTH-induced
ERK1/2-phosphorylation was then found to be enhanced and
prolonged in the presence of BAM22 (Figure 5E). To further
examine whether this modulation of ERK1/2 is required for
enhanced cortisol secretion, H295R cells were treated with
U0126, a selective inhibitor for MEK1/2, upstream activators of
ERK1/2. U0126 treatment decreased the basal ACTH-induced
cortisol secretion and blocked the stimulatory effects of
BAM22 (Figure 5F). Collectively, these data support our signaling
model (Figure 6A).
Activation of CXCR7 Is Sufficient to Induce Anxiolytic-
like Behavior
Our results suggest that the opioid-CXCR7-glucocorticoid
pathway is a hormonal axis linking adrenal tissue remodeling
to anxiolytic-like behavior (Figure 6A). Identification of this axis
prompted us to test whether activation of CXCR7 by a synthetic
ligand is sufficient to induce anxiolytic-like behavior. CCX771 is a
small molecule compound with highly specific activity against
CXCR7 (Zabel et al., 2009). Because of its favorable pharmoki-
netics, in vivo use of this compound has been well established
(Cruz-Orengo et al., 2011). As previously reported, CCX771
binds to CXCR7 and efficiently recruits b-arrestins (Figures 6B
and S5A) (Zabel et al., 2009). Utilizing cultured adrenocortical
cells and isolated adrenal slices, we further confirmed that
CCX771 augments glucocorticoid secretion in the presence of
ACTH (Figures 6C, 6D, and S5B). Six-month-old female mice
were then treated with CCX771. Subcutaneous twice-a-day in-
jection at a dose of 5 mg/kg for 3 days resulted in increasedFigure 5. CXCR7 Mediates the Enhanced Circadian Glucocorticoid Os
(A) In situ hybridization with cRNA probes for Cxcr7, Oprd1, Oprk1, Oprm1, andM
500 mm.
(B) Effects of CXCR7-neutralizing antibody treatment on enhanced circadian gluco
(C) Effects of CXCR7 knockdown on enhanced cortisol secretion by BAM22.
(D) Effects of b-arrestin-1 and b-arrestin-2 knockdown on enhanced cortisol sec
(E) Enhanced ACTH-induced ERK1/2 phosphorylation by BAM22 (3 mM).
(F) Effects of U0126 (1 mM) treatment on the stimulatory action of BAM22.
Results are shown as mean ± SEM. *p < 0.05; **p < 0.01. See also Figure S4 ancirculating glucocorticoid levels at ZT12, while no effect was
observed at ZT0 (Figures 6E and 6F). These endocrinological
changes induced by CCX771 treatment were consistent with
what we observed in female mice with SCH. Importantly, there
was no difference in circulating ACTH levels, eliminating the
possibility that CCX771 modulates glucocorticoid secretion by
stimulating the upstream components of the HPA axis (Fig-
ure S5C). As predicted from the sex-dependent adrenocortical
expression of Cxcr7 (Figure 5A), CCX771 exerted no stimulatory
effect on glucocorticoid secretion in males (Figure S5D). Having
observed the increased amplitude of circadian glucocorticoid
secretion by CCX771, we then tested its behavioral effects. In
the elevated plus maze test, female mice treated with CCX771
displayed anxiolytic-like behavior, which was dependent on
glucocorticoid signaling (Figures 6G and 6H). These results indi-
cate that the activation of CXCR7 signaling in the glucocorticoid-
producing cells is sufficient to induce anxiolytic-like behavior.
DISCUSSION
The peripheral endocrine systems communicate with the brain
by secreting hormones, which potentially alter the information-
processing properties of neural circuits underlying behavior.
Overproduction of glucocorticoids from adrenal tumors is known
to cause Cushing syndrome. Patients with Cushing syndrome
display psychiatric abnormalities including anxiety, depression,
and cognitive function deficits (Starkman et al., 1981; Wolkowitz
et al., 2009). Similarly, chronic glucocorticoid administration in
mice results in increased anxiety/depression-like behavior (Da-
vid et al., 2009). Pharmacologic strategies aimed at correcting
overactivated glucocorticoid signaling, such as glucocorticoid
biosynthesis inhibitors and glucocorticoid receptor antagonists,
have been utilized for the treatment of Cushing syndrome
(Wolkowitz et al., 2009). These antiglucocorticoid treatments
have also been reported to act synergistically with selective
serotonin reuptake inhibitors in depressed patients (Jahn et al.,
2004), indicating that modulation of biological effects of periph-
erally released hormones has therapeutic potential in neurolog-
ical and psychiatric disorders.
The adrenal glands, the main peripheral source of glucocorti-
coids, have a remarkable tissue plasticity that allows their
remodeling with age (Bland et al., 2003). SCH, one of the charac-
teristics of adrenal tissue remodeling, is histologically distinct
from tumors and dysplasia (Kim et al., 2005; Kovatch et al.,
1986; Yoshida et al., 1986). We have now demonstrated that
SCH is functionally different as well. In contrast to adrenocortical
tumor cells that secrete steroids, SCH cells secrete intermediate
opioid peptides as paracrine hormones. These peptides
enhance the circadian oscillation of glucocorticoids withoutcillation Induced by SCH
rgprx1. 2mo, 2 months old; 4mo, 4 months old; 6mo, 6 months old. Scale bar,
corticoid oscillation induced by SCH (ZT0: n = 4/group; ZT12: n = 7–16/group).
retion by BAM22.
d Table S3.
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affecting their total daily secretion or HPA axis regulation. The
glucocorticoid oscillation is required to maintain circadian activ-
ities in certain brain regions (Lamont et al., 2005; Malek et al.,
2007). Likewise, mice designed to have an attenuated circadian
glucocorticoid oscillation exhibit altered locomotor activity (Son
et al., 2008). These findings suggest that circadian glucocorti-
coid oscillation influences behavior. However, the exact physio-
logical relevance of circadian glucocorticoid oscillation in the
regulation of emotional behavior has remained unknown. By
demonstrating anxiolytic-like effects of SCH, we here provide
evidence that enhancing circadian glucocorticoid oscillation,
without affecting the HPA axis, is sufficient to alter emotional
states. Furthermore, we propose that enhancing the amplitude
of glucocorticoid oscillation can be anxiolytic in certain contexts,
even though glucocorticoids are generally considered an anxio-
genic factor. This is analogous to the previous hypothesis that a
marked rise of glucocorticoid levels, accompanied by a return to
the basal state, provides an organism with the ability to adapt to
stress (Kudielka and Kirschbaum, 2005). Our results reinforce
the idea that circadian glucocorticoid oscillation is involved in
higher brain functions regulating emotional behavior.
In this report, we have shown that the Proenkephalin A gene,
which encodes one of the peptide precursors that produce
endogenous opioid peptides, is expressed in the adrenal SCH.
SCH cells secrete intermediate opioid peptides such as
BAM22 and peptide E because of the lack of PCSK2, a prohor-
mone convertase required for the full processing to mature
enkephalins. BAM22 and peptide E act as endogenous ligands
for CXCR7 and exert anxiolytic-like effects by enhancing circa-
dian glucocorticoid oscillation in the adrenal glands. In contrast,
neurons mainly produce mature enkephalins, which act as
endogenous ligands for DOR in the central nervous system
(CNS). Based on genetic evidence that both proenkephalin A
and DOR knockout mice display increased anxiety-like behavior
(Filliol et al., 2000; Ko¨nig et al., 1996), enkephalin-DOR signaling
is considered one of the endogenous peptidergic systems that
exert anxiolytic-like effects in the CNS. These findings suggest
that both intermediate opioid peptides in the adrenal glands
and mature enkephalins in the CNS elicit similar behavioral
effects, although a totally different ligand-receptor system is
involved in each case. We here offer a unifying hypothesis that
proenkephalin A gene products exert anxiolytic-like effects in
both the CNS and the periphery.
A surprising discovery presented in this report is the identifica-
tion of CXCR7 as a high-affinity receptor for intermediate opioid
peptides, since CXCR7 is known as a receptor for the chemo-
kines SDF1 and I-TAC (Burns et al., 2006; Rajagopal et al.,
2010). The chemokine receptor family is structurally distinctFigure 6. Activation of CXCR7 by CCX771 Is Sufficient to Induce Anxio
(A) Schematic of the opioid-CXCR7-glucocorticoid pathway (gray rectangle) link
(B) Activation of CXCR7 by CCX771 in a b-arrestin-2 recruitment assay.
(C) CCX771 enhanced cortisol secretion from H295R cells in the presence of AC
(D) CCX771 (100 nM) augmented corticosterone secretion in isolated adrenal slic
(E) CCX771 injection regimen.
(F) Increased circadian amplitude of glucocorticoid secretion by CCX771 (n = 6–
(G) Anxiolytic-like effects of CCX771 in the elevated plus maze test (n = 17–18/g
(H) Effects of a glucocorticoid receptor antagonist (RU486; 20 mg/kg for 3 days)
Mice without SCH were used for (F)–(H). Results are shown as mean ± SEM. *pfrom the canonical opioid receptor family. In agreement with
this structural difference, we demonstrate that the complete
opioid motif is not required for CXCR7 activation and that
CXCR7 acts as a specific receptor for intermediate opioid
peptides, but not for mature enkephalins. Furthermore, the
BAM22-CXCR7 interaction is distinct from the interaction of
BAM22 with canonical opioid receptors in its insensitivity to
naloxone. Our results point to a previously unrecognized link
between the opioid and chemokine systems and raise the possi-
bility that other peptide precursors may also play unexpected
roles by encoding additional ligands.
We have demonstrated that CXCR7 ligands modulate circa-
dian glucocorticoid oscillation by enhancing its amplitude
without changing its period or phase. These in vivo results led
us to speculate that CXCR7 ligands act synergistically with
ACTH. Indeed, in vitro, both endogenous and synthetic CXCR7
ligands do not have any stimulatory effects on glucocorticoid
secretion per se but promote glucocorticoid secretion in the
presence of ACTH. This stimulatory action of CXCR7 ligands is
analogous to the insulinotropic action of glucagon-like peptide-
1 (GLP-1), one of the incretins secreted following nutrient inges-
tion, which stimulates insulin secretion in pancreatic beta cells
strictly in a glucose-dependent manner (Marathe et al., 2013).
Interestingly, SCH does not affect the acute stress-induced
glucocorticoid synthesis that is partly mediated by the nonge-
nomic effects of ACTH. This suggests that the CXCR7-b-
arrestin-MAPK pathway selectively influences the chronic
effects of ACTH by modulating the expression of genes required
for basal circadian glucocorticoid production (Arakane et al.,
1997; Gallo-Payet and Payet, 2003). CXCR7 ligand treatments
lead to enhanced circadian glucocorticoid oscillation, because
their effects are only significant at ZT12. This observation may
be explained by recent findings that adrenocortical cells have
their own circadian clock machinery, which renders cells more
sensitive to extracellular stimuli at the beginning of the activity
phase (ZT12) (Oster et al., 2006). To our knowledge, synthetic
CXCR7 ligands are the first pharmacological tool available to
manipulate circadian glucocorticoid oscillation in vivo. Although
synthetic CXCR7 ligands canmodulate neither period nor phase,
they offer a simple means of studying physiological and behav-
ioral consequences of changing the circadian amplitude of
glucocorticoid oscillation.
Marked sex differences have been reported in adrenal size,
circulating glucocorticoid levels, and gene expressions in the
adrenal cortex (Bastida et al., 2007; Bielohuby et al., 2007). We
have found that CXCR7 is expressed in the adrenal glucocorti-
coid-producing cells in a highly sex-dependent manner, which
in turn explains the sex differences in the endocrinological andlytic-like Behavior
ing adrenal tissue remodeling to behavior.
TH (+; 300 nM, ++; 1 mM).
es from 6-month-old female mice in the presence of ACTH (n = 6–10/group).
8/group).
roup).
on anxiolytic-like behavior induced by CCX771 treatment (n = 6–8/group).
< 0.05; **p < 0.01. See also Figure S5.
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behavioral effects of SCH. Females are reported to have
enhanced stress sensitivity and a greater predisposition to
stress-related disorders such as depression (Becker et al.,
2007). An increased occurrence of stress-related disorders after
puberty indicates that sex hormones act as powerful modulators
of emotional behavior (Kudielka and Kirschbaum, 2005). How-
ever, all sex-related influences on brain function and behavior
cannot be explained by the action of sex hormones, since
many sex differences are known to persist even without these
hormones. Thus, it is evident that sex-related influences on
behavior and their underlying mechanisms are enormously
diverse (Cahill, 2006). The sex-dependent effects of SCH sup-
port this hypothesis and may add another layer of complexity
to this diversity.
In summary, we unexpectedly observed that mice with SCH
are less anxious thanmice without SCH. SCH cells secrete inter-
mediate opioid peptides as paracrine hormones and they exert
anxiolytic-like effects by enhancing circadian glucocorticoid
oscillation. Based on our discovery that CXCR7 functions as a
receptor for these opioid peptides, we could recapitulate the
biological effects of SCH by administering a synthetic CXCR7
ligand. By identifying the biological functions of adrenal SCH,
we have shown that modulation of circadian glucocorticoid
oscillation by enhancing its amplitude leads to altered emotional
states and that b-arrestin signaling in the adrenal glucocorticoid-
producing cells is a potential target for affecting glucocorticoid
oscillation and emotional behavior.
EXPERIMENTAL PROCEDURES
All animal experiments were performed under protocols approved by the Insti-
tutional Animal Care and Use Committee and were strictly in accordance with
NIH guidelines. Extended Experimental Procedures are available online.
In Vivo Experiments
For the hormone measurements, blood samples were collected within 30 s of
disturbance. Corticosterone and ACTH were measured using commercially
available radioimmunoassay and ELISA kits, respectively. After blood collec-
tion, both adrenal glands were harvested for histological analysis. Mice with
bilateral SCH, which occupies more than one-third of the adrenal circumfer-
ence, were judged as SCHpositive. Sampleswere grouped based on the pres-
ence and absence of the adrenal SCH. For female mice, vaginal smears were
performed immediately after each experiment to evaluate the estrus cycle, and
similar distributions of the estrus-cycle phases were confirmed between the
comparing groups. Dexamethasone 21-phosphate was injected intraperitone-
ally 6 hr before serum sample collection. Behavioral tests (open field test,
elevated plus maze test, light-dark box test, and forced swim test) were
performed at ZT12 as previously described (Crawley, 1981; Lister, 1987; Por-
solt et al., 1977; Willie et al., 2008). The glucocorticoid receptor antagonist
RU486 (20mg/kg) was injected intraperitoneally for 4 days at ZT6. Neutralizing
antibody against CXCR7 (anti-CXCR7 mAb [8F11]; 10 mg/kg) was injected
intraperitoneally and serum samples were collected 96 hr after the injection.
CCX771 (kindly provided by ChemoCentryx) was administered subcutane-
ously twice a day (ZT0 and ZT6) at the dose of 5 mg/kg for 3 days as a solution
in 10% Captisol. The endocrinological and behavioral effects of CCX771 were
evaluated using mice without SCH.
b-Arrestin-GPCR Recruitment Assay
293T cells were stably transfected with b-arrestin-1/2-u (u: M15 deletion
mutant of b-galactosidase) chimera to establish a reporter cell line (293T/ba-
M15). 293T/ba-M15 cells were transiently transfected with multiple GPCR-a
(a short a peptide fragment of b-galactosidase) chimeras of interest. Cells1334 Cell 155, 1323–1336, December 5, 2013 ª2013 Elsevier Inc.were stimulated with agonists in OPTI-MEMI/0.1% BSA followed by 90 min
of incubation at 37C. Gal-Screen substrate was added to the wells and the
plates were further incubated for 90 min at 25C. Luminescence was
measured in a plate reader (Victor V; Perkin Elmer).
Radioligand Binding Assay
293T cells, stably expressing human CXCR7 (hCXCR7), were harvested in the
extraction buffer (50 mM Tris-HCl [pH 7.5], 5 mM MgCl2 and protease inhibitor
cocktail) and5mgofmembrane fractionwas incubatedwith0.1nMof radioligand
and various concentrations of unlabeled ligands in the binding buffer (50 mM
Tris-HCl [pH 7.5], 500 mM NaCl, 2 mM EDTA, 0.25 M sucrose, and 0.1%
BSA). After 90 min incubation at 4C, the bound ligand was separated from the
free ligand by filtering. The amount of the radioligand bound to the receptor
was determined by measuring the radioactivity on the filter using a g counter.
Lentivirus-Mediated RNAi
The pLKO-EGFP-IRES-puro vector was generated from pLKO-puro vector
(Sigma-Aldrich) with modifications. Small hairpin RNAs (shRNAs) for hCXCR7,
hb-arrestin-1 and hb-arrestin-2 were designed based on Mission shRNA data-
base (Sigma-Aldrich). Sequences for shRNAs were inserted into the pLKO-
EGFP-IRES-puro vector. H295R cells were infected with the viruses in the
presence of polybrene (8 mg ml1) for 18 hr and then the medium was re-
newed. After 5 days, the medium was removed and ligands in serum-free
medium were added to the well followed by 24 hr of incubation at 37C.
Statistical Analyses
Results are expressed as the mean ± SEM. Differences between two groups
were assessed by unpaired two-tailed t tests. Data involving multiple groups
were assessed by ANOVA.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and three tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2013.10.052.
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